Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 10, 2020

SELL
$2.63 - $8.09 $53,652 - $165,036
-20,400 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$5.69 - $8.17 $3,414 - $4,902
600 Added 3.03%
20,400 $135,000
Q1 2020

May 15, 2020

BUY
$5.47 - $11.3 $108,306 - $223,740
19,800 New
19,800 $115,000

Others Institutions Holding GRTS

About Gritstone bio, Inc.


  • Ticker GRTS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,006,896
  • Market Cap $2.19M
  • Description
  • Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...
More about GRTS
Track This Portfolio

Track Td Asset Management Inc Portfolio

Follow Td Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Td Asset Management Inc with notifications on news.